# US 2024/0190861 A1 · Aminopyrimidine compound as cdk2/4/6 triple inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0190861 A1
- Document ID: US20240190861A1
- Status: Published application
- Kind: A1
- Application number: 17/769,385
- Filed: 2020-10-16
- Published: 2024-06-13
- Earliest claimed: 2019-10-17
- Assignees: Cisen Pharmaceutical Co., Ltd.
- Applicants: Cisen Pharmaceutical Co., Ltd
- Inventors: Ming ZHOU; Zhaobing XU; Gang LI; Lihong HU; Charles Z. DING; Wen JIANG; Guoping HU; Jian LI; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20240190861A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is an aminopyrimidine compound as a CDK2/4/6 inhibitor, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and an application of the compound represented by formula (I) and the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating solid tumor.

## Claims

### Claim 1

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
T is N or CH;
R1 is C4-6 cycloalkyl, wherein the C4-6 cycloalkyl is substituted with 1, 2 or 3 Ra;
each Ra is independently F, Cl, Br, I, —CN, —OH, C1-3 alkoxy or C1-3 alkyl, wherein the C1-3 alkoxy and the C1-3 alkyl are optionally substituted with 1, 2 or 3 substituents independently selected from F, Cl, Br, —CN, —OH and —NH2;
R2 and R3 are each independently H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy or C1-3 alkyl, wherein the C1-3 alkoxy and the C1-3 alkyl are optionally substituted with 1, 2 or 3 substituents independently selected from F, Cl, Br, —CN, —OH and —NH2;
or R2 and R3 are joined together with the carbon atom to which they are attached form C3-5 cycloalkyl, wherein the C3-5 cycloalkyl is optionally substituted with 1, 2 or 3 Rb;
each Rb is independently H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy, C1-3 alkyl or C1-3 haloalkyl;
R4 and R5 are each independently H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy or C1-3 alkyl, wherein the C1-3 alkoxy and the C1-3 alkyl are optionally substituted with 1, 2 or 3 substituents independently selected from F, Cl, Br, —CN, —OH and —NH2;
or R3 and R4 are joined together with the carbon atom to which they are attached form C3-5 cycloalkyl, wherein the C3-5 cycloalkyl is optionally substituted with 1, 2 or 3 Rc;
each Rc is independently H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy, C1-3 alkyl or C1-3 haloalkyl;
R6 is H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy, C1-3 alkyl or C1-3 haloalkyl;
R7 is —NH2, C1-3 alkylamino, C1-6 alkyl, C3-5 cycloalkyl, 4- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl, wherein the C1-6 alkyl, the C3-5 cycloalkyl, the 4- to 6-membered heterocycloalkyl, the 5- to 6-membered heteroaryl and the phenyl are optionally substituted with 1, 2 or 3 Rd;
each Rd is independently H, F, Cl, Br, I, —CN, —OH, C1-3 alkoxy or C1-3 alkyl, wherein the C1-3 alkoxy and the C1-3 alkyl are optionally substituted with 1, 2 or 3 substituents independently selected from F, Cl, Br, —CN, —OH and —NH2;
n is 0, 1 or 2;
the 4- to 6-membered heterocycloalkyl and the 5- to 6-membered heteroaryl respectively comprise 1, 2, 3 or 4 heteroatoms independently selected from N, —O— and —S—.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein each Ra is independently F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3 or —CH2CH3,
or, each Rb is independently H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3 or —CH2CH3;
or, each Rc is independently H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3 or —CH2CH3;
or, each Rd is independently H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3, —CH2CH3 or —CH(CH3)2;
or, R2 and R3 are joined together with the carbon atom to which they are attached form cyclopropyl, wherein the cyclopropyl is optionally substituted with 1, 2 or 3 Rb;
or, R3 and R4 are joined together with the carbon atom to which they are attached form cyclopropyl, wherein the cyclopropyl is optionally substituted with 1, 2 or 3 Rc.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is
wherein the
are optionally substituted with 1, 2 or 3 Ra.

### Claim 4 (depends on 3)

The compound or the pharmaceutically acceptable salt thereof according to claim 3, wherein R1 is

### Claim 5 (depends on 4)

The compound or the pharmaceutically acceptable salt thereof according to claim 4,
wherein R1 is

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, the compound has the structure represented by formula (I-1):
wherein, R2, R3, R4, R5, R6, R7, Ra and n are as defined above, p is 1, 2 or 3.

### Claim 7 (depends on 6)

The compound or the pharmaceutically acceptable salt thereof according to claim 6, the compound has a structure represented by formula (I-2)-(I-7):
wherein, R2, R3, R4, R5, R6, R7, Ra, Rb, Rc, T, p, and n are as defined above, q is 0, 1, 2 or 3.

### Claim at position 8

8-13. (canceled)

### Claim 14 (depends on 7)

The compound or the pharmaceutically acceptable salt thereof according to claim 7, the compound has a structure represented by any structural formula of formula (I-8)-(I-12):
wherein, Ra, Rb, Rc, T, R6, R7, p and q are as defined above.

### Claim 15 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2 and R3 are each independently H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3 or —CH2CH3;
or, R4 and R5 are each independently H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, —CF3 or —CH2CH3;
or, R6 is H, F, Cl, Br, I, —CN, —OH, —OCH3, —CH3, or —CH2CH3.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R7 is —NH2, —NH(CH3), —NH(CH2CH3), —N(CH3)2, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, cyclopropyl, cyclopentyl, azacyclobutyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, pyrazolyl, pyridyl or phenyl, wherein the —CH3, the —CH2CH3, the —CH2CH2CH3, the —CH(CH3)2, the cyclopropyl, the cyclopentyl, the azacyclobutyl, the pyrrolidinyl, the tetrahydrofuranyl, the piperidinyl, the pyrazolyl, the pyridyl or the phenyl are optionally substituted with 1, 2 or 3 Rd.

### Claim 19 (depends on 18)

The compound or the pharmaceutically acceptable salt thereof according to claim 18, wherein R7 is —NH2, —NH(CH3), —NH(CH2CH3), —N(CH3)2, —C(Rd)3, —CH2CH2Rd,

### Claim 20 (depends on 19)

The compound or the pharmaceutically acceptable salt thereof according to claim 19, wherein R7 is —NH2, —NH(CH3), —N(CH3)2, —CH3, —CF3, —CH2CH3, —CH(CH3)2, —CH2CH2OCH3,

### Claim 21

A compound of the following formula or a pharmaceutically acceptable salt thereof:

### Claim 22

A compound of the following formula or a pharmaceutically acceptable salt thereof:

### Claim 23 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

### Claim 24 (depends on 1)

A pharmaceutical composition, which comprises a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 1)

A method for inhibiting CDK2/4/6 activity in a subject in need thereof, comprising administrating to the subject a medicament comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 26 (depends on 1)

A method for treating solid tumor in a subject in need thereof, comprising administrating the compound or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the solid tumor is colorectal cancer or breast cancer.
